Regulatory Strategy

FDA-focused regulatory consulting for digital health technologies, software as a medical device classification, and clinical endpoint qualification in neuroscience.

Discuss Your Program

The regulatory landscape for digital health and CNS clinical measurement is evolving rapidly. The FDA is actively developing frameworks for digital endpoints, software as a medical device, and AI-driven clinical tools. Sponsors who understand this landscape and engage proactively with the agency will gain significant advantages over those who treat regulatory strategy as an afterthought.

We bring deep specialization in the intersection of regulatory science and CNS clinical measurement. Our focus is on ensuring that your measurement tools, endpoints, and data collection strategies meet the standards regulators expect, and on building the evidentiary packages that facilitate constructive regulatory dialogue.

Whether you are developing a novel digital biomarker, seeking qualification for a clinical outcome assessment, or navigating the SaMD regulatory pathway, we provide the strategic guidance to get you from development to submission with confidence.

What We Deliver

FDA Engagement Strategy

Strategic planning for pre-submission meetings, breakthrough device designation applications, and ongoing regulatory dialogue throughout development.

SaMD Classification & Pathway

Navigate software as a medical device classification, identify the appropriate regulatory pathway, and build the technical documentation required for clearance or approval.

Endpoint Qualification

Develop the evidentiary package for clinical endpoint qualification, including biomarker qualification submissions to the FDA Biomarker Qualification Program.

Regulatory Submission Support

Prepare endpoint-related sections of INDs, NDAs, and BLAs with the depth and precision that regulatory reviewers expect.

Guidance & Precedent Analysis

Monitor and interpret evolving FDA guidance on digital health, clinical outcome assessments, and CNS-specific regulatory expectations.

Risk-Based Regulatory Planning

Identify regulatory risks early in development and build mitigation strategies into your program timeline before they become costly delays.

Typical Deliverables

Regulatory strategy documents
Pre-submission meeting packages
SaMD classification analyses
Endpoint qualification dossiers
Regulatory gap analyses
FDA guidance interpretation briefs
Submission-ready endpoint narratives
Risk assessment and mitigation plans
Regulatory precedent research reports

Navigate the regulatory landscape with clarity

Let us help you build a regulatory strategy that turns measurement innovation into regulatory acceptance.

Start the Conversation